OrbiMed

Mineralys Therapeutics Announces $120 Million Private Placement Financing

Retrieved on: 
星期四, 二月 8, 2024
Security (finance), Research, Exercise, BofA Securities, PIPE, Hypertension, OrbiMed, Therapy, Sale, Chronic kidney disease

In the PIPE, Mineralys is selling an aggregate of approximately 8.9 million shares of its common stock (or pre-funded warrants in lieu thereof) at a price of $13.50 per share (or $13.499 per pre-funded warrant).

Key Points: 
  • In the PIPE, Mineralys is selling an aggregate of approximately 8.9 million shares of its common stock (or pre-funded warrants in lieu thereof) at a price of $13.50 per share (or $13.499 per pre-funded warrant).
  • The pre-funded warrants will have an exercise price of $0.001 per share of common stock, will be immediately exercisable and will not expire.
  • Mineralys expects to use the net proceeds from the PIPE to fund the research and development of lorundrostat, and for working capital and general corporate purposes.
  • BofA Securities and Evercore are acting as placement agents to the Company in connection with the PIPE.

Michael Austwick Joins Verona Pharma as Non-Executive Director

Retrieved on: 
星期四, 二月 1, 2024
Bachelor of Science, University, Head, Novartis, City University, VRNA, Information management, AstraZeneca, OrbiMed, Master of Science

LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director.

Key Points: 
  • LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director.
  • Mr. Austwick has led the development and commercialization of more than 10 brands, covering inhaled and biologic assets at a country and global level.
  • “We are delighted to welcome Michael to the Board,” said Dr. David Ebsworth, Chairperson of Verona Pharma.
  • Dr. Ebsworth added: “We would like to thank Rishi for his numerous contributions to Verona Pharma’s successful development over the past 7 years.

Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock

Retrieved on: 
星期五, 一月 19, 2024
Biotechnology, Pharmaceutical, Health, Cardiology, Janus, Citadel, Myopathy, Patient, Therapy, Research, SVB Securities, OrbiMed, Edgewise, Prospectus, Novo Holdings A/S, Form, Sale, Becker muscular dystrophy, ATTN:, Montgomery Street, Attention, Telephone, State Street

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share.

Key Points: 
  • Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share.
  • Edgewise anticipates gross proceeds from the offering to be approximately $240 million, before deducting underwriting discounts and commissions and offering expenses.
  • The closing of the offering is expected to occur on January 23, 2024, subject to the satisfaction of customary closing conditions.
  • A prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC.

Edison issues review on Worldwide Healthcare Trust (WWH): Scope for the trust to get back on track in 2024

Retrieved on: 
星期一, 一月 8, 2024
OrbiMed, Trust, History

Worldwide Healthcare Trust’s (WWH’s) co-managers, Sven Borho and Trevor Polischuk, at global healthcare specialist OrbiMed, are disappointed with WWH’s performance as, in recent years, the trust has faced both top-down and bottom-up headwinds.

Key Points: 
  • Worldwide Healthcare Trust’s (WWH’s) co-managers, Sven Borho and Trevor Polischuk, at global healthcare specialist OrbiMed, are disappointed with WWH’s performance as, in recent years, the trust has faced both top-down and bottom-up headwinds.
  • A combination of above-average investor risk aversion and lacklustre relative performance has weighed on the trust’s valuation.
  • WWH’s double-digit discount, which is wider than its historical averages, could provide an additional opportunity when sentiment towards healthcare stocks improves and/or the trust’s relative performance gets back on track.
  • WWH’s shares should now be more accessible to retail investors following a 10:1 share split in July 2023.

Domain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology Company

Retrieved on: 
星期一, 一月 8, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, OrbiMed, Multimedia, AstraZeneca, Gq alpha subunit, Research, Physician, Fellow, Therapy, Cancer, GSK, PNT, University, Royal Australasian College, GPCR, Growth, Patient, Bristol Myers Squibb, Management

View the full release here: https://www.businesswire.com/news/home/20240108886645/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240108886645/en/
    Michael’s appointment as Chairman follows Laurence Rulleau and Youssef Bennani, who held the role for 9 years.
  • An industry expert with international experience leading biopharmaceutical companies, Michael is also currently the President and Chief Executive Officer of RENOGENYX.
  • As the new President and CEO, based in Boston, Tony succeeds Pascal Neuville who founded and successfully led the Company for the past 15 years.
  • Their respective expertise and track record in pioneering and leading biopharmaceutical companies will be invaluable to the Company and will support our reach and global focus.

Biotech Veteran Marc Yoskowitz Named Evozyne CEO

Retrieved on: 
星期四, 一月 4, 2024
Professional Services, Health, Technology, Finance, General Health, Artificial Intelligence, Biotechnology, Paragon, Pfizer, McKinsey & Company, Drug discovery, Protein, OrbiMed, Hospira, Tempus, Patient, NVIDIA

Chicago-based Evozyne today announced Marc Yoskowitz as CEO of the generative AI-driven biotech.

Key Points: 
  • Chicago-based Evozyne today announced Marc Yoskowitz as CEO of the generative AI-driven biotech.
  • Yoskowitz has held executive leadership positions with Pfizer, Hospira and McKinsey & Company, bringing deep biopharmaceutical, corporate development and strategy expertise to the role.
  • Leading a company that is pioneering this technology and developing novel proteins is an unparalleled opportunity,” Yoskowitz said.
  • Founded in 2020 by Paragon Biosciences, Evozyne develops novel proteins that solve high-impact problems in human health.

OrbiMed Invests in Strategic Partnership With Nanotronics

Retrieved on: 
星期五, 一月 5, 2024
Technology, Professional Services, Nanotechnology, Software, Hardware, General Health, Health, Data Management, Asset Management, Artificial Intelligence, Artificial intelligence, Artificial intelligence in industry, OrbiMed, Industrial, Partnership, General partnership, Quality control, Multimedia

Nanotronics , the Industrial AI company, today announced a new strategic partnership with OrbiMed , a leading global life sciences investment firm.

Key Points: 
  • Nanotronics , the Industrial AI company, today announced a new strategic partnership with OrbiMed , a leading global life sciences investment firm.
  • As part of the transaction, OrbiMed is investing in Nanotronics’ proprietary technology to advance quality control and precision manufacturing across the healthcare and biotech industries.
  • This press release features multimedia.
  • “The sooner healthcare companies embrace Artificial Intelligence for manufacturing and quality control, the quicker we will see improved patient outcomes.”

ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome

Retrieved on: 
星期三, 一月 3, 2024
Research, Finance, FDA, Clinical Trials, Professional Services, Other Health, Biotechnology, Pharmaceutical, Health, Science, Food, FXR, Multimedia, IND, Kidney, Chronic kidney disease, OrbiMed, EMA, Trial of the century, ODD, Clinical trial, ADPKD, Kidney disease, European Medicines Agency, Patient, EGFR, Fibrosis, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240103067331/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240103067331/en/
    Furthermore, ENYO announced the first closing of a 39 million € Series C equity financing, positioning ENYO as an emerging biotechnology company in the field of renal diseases.
  • The financing will support the Phase 2 Alpestria-1 study and further profiling of Vonafexor in other kidney diseases, such as Autosomal Dominant Polycystic Kidney Disease (ADPKD).
  • The clearance of ENYO’s IND represents a significant milestone for the company as it embarks on its first clinical trial focusing on renal disease.
  • ENYO’s lead candidate Vonafexor, as well as fast follower EYP651, are highly specific FXR agonists given as once-daily oral treatments.

Q32 Bio and Homology Medicines Announce Merger Agreement

Retrieved on: 
星期四, 十一月 16, 2023
Bristol Myers Squibb, ANCA, AA, Clinical trial, Patient, Alopecia areata, Atopic dermatitis, Therapy, Q32, OrbiMed, Trial of the century, TSLP, IL-7, System, Autoimmunity, AAV, OUP, Vaccine, Pharmaceutical industry

WALTHAM, Mass. and BEDFORD, Mass., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc. (Nasdaq: FIXX), today announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Q32 Bio’s wholly owned clinical development candidates for the treatment of autoimmune and inflammatory diseases. Upon completion of the merger, the combined company will operate as Q32 Bio, headquartered in Waltham, Massachusetts, and is expected to trade under the Nasdaq ticker symbol “QTTB”.

Key Points: 
  • and BEDFORD, Mass., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc. (Nasdaq: FIXX), today announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
  • The combined company will focus on advancing Q32 Bio’s wholly owned clinical development candidates for the treatment of autoimmune and inflammatory diseases.
  • Upon completion of the merger, the combined company will operate as Q32 Bio, headquartered in Waltham, Massachusetts, and is expected to trade under the Nasdaq ticker symbol “QTTB”.
  • “The proposed merger with Homology Medicines and concurrent private placement is expected to provide Q32 Bio with the capital to drive development of our autoimmune and inflammatory pipeline through multiple clinical milestones,” said Jodie Morrison, Chief Executive Officer of Q32 Bio.

Odyssey Therapeutics Announces $101 Million Series C Financing

Retrieved on: 
星期二, 十二月 5, 2023
FDA, Other Health, Finance, Pharmaceutical, Business, Oncology, General Health, Professional Services, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Science, Other Science, Research, Health, Foresite Capital, Therapy, Ideation, Patient, Investment, Goldman Sachs, Messenger, SVB Securities, OrbiMed, Drug discovery, HBM, Drug development, Pharmaceutical industry, Boston, Odyssey

This Series C financing brings the total capital raised since founding in late 2021 to $487 million.

Key Points: 
  • This Series C financing brings the total capital raised since founding in late 2021 to $487 million.
  • Proceeds will support the advancement of multiple programs into clinical studies and the continuation of investment in discovery to build a sustainable model for therapeutic innovation.
  • This unique set of tools enables Odyssey to identify drug targets with the highest clinical potential in a modality-agnostic fashion.
  • “Odyssey continues to accelerate multiple pre-clinical programs in immunology and oncology,” said Jeff Leiden, M.D., Ph.D., Chairman of the Odyssey board.